P-043 - CHEMORADIATION TREATMENT FOR ANAL CARCINOMA: SINGLE INSTITUTION ANALYSIS
P-044 - CHEMORADIOTHERAPY (CRT) IN LOCALLY ADVANCED PANCREATIC CANCER (LAPC).
P-045 - CHEMORADIOTHERAPY AND DURVALUMAB CONSOLIDATION FOR UNRESECTABLE STAGE III NSCLC
P-046 - CHEST WALL PAIN IN LUNG SBRT PATIENTS: DOSE-VOLUME CORRELATIONS
P-047 - Chronic toxicity results in early-stage breast cancer using Fast-Forward
P-048 - CLINICAL AND PATHOLOGICAL RESPONSE TO TNT FOR LOCAL RECTAL CANCER
P-049 - Clinical experience after high-dose radiotherapy for locally advanced esophageal cancer
P-050 - CLINICAL IMPLICATION OF DIFFERENT TREATMENT TECHNIQUES IN GLOTTIC CANCER
P-051 - CLINICAL OUTCOMES OF SOLITARY PULMONARY NODULE TREATED WITH SBRT
P-052 - CLINICAL OUTCOMES OF TWO RADIOTHERAPY SCHEDULES FOR SPINAL CORD COMPRESSION
P-053 - CLINICAL, DOSIMETRIC AND RADIOBIOLOGICAL FACTORS FOR TOXICITY IN SKIN BT
P-054 - COMBINED RADIOTHERAPY, EXTERNAL PLUS BRACHYTHERAPY IN PROSTATE CANCER: LONG-TERM RESULTS
P-055 - COMPARATION IORT TECHNIQUES IN SOFT TISSUE SARCOMAS IN ONE CENTRE
P-056 - COMPARISON BETWEEN TREATMENT OPTIONS FOR BREAST-DCIS: CLINICAL OUTCOMES AND QUALITY-OF-LIFE
P-057 - COMPARISON OF DOSE CALCULATION ALGORITHMS IN BRACHYTHERAPY.
P-058 - COMPARISON OF TWO APPLICATIONS FOR RISK MATRIX METHODOLOGY IN RADIOTHERAPY
P-059 - COMPARISON SBRT TREATMENT TIME FOR 6 - 10 FFF
P-060 - CONSULTATION OPTIMIZATION IN PATIENTS WITH HEAD AND NECK (H&N) CANCER
P-061 - CONTROVERSY IN RARE TUMORS: OUR ROLE IN PAROTID SMALL-CELL CARCINOMA
P-062 - COVID19 PANDEMIC INFLUENCE ON BREAST EXTREME-HYPOFRACTIONATION IMPLEMENTATION: OUR EXPERIENCE
P-063 - CPRC M0: AN INSTITUTIONAL EXPERIENCE